NCT05944458View on ClinicalTrials.gov

Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2025

Conditions
LinezolidAntioxidantThrombocytopeniaCritical IllnessICU
Interventions
DRUG

N acetyl cysteine

Fluimucil 600 mg iv to be taken twice daily as infusion

DRUG

Placebo

20 ml normal saline iv every 12 hours

Trial Locations (1)

Unknown

15 May hospital, Cairo

All Listed Sponsors
lead

Helwan University

OTHER